Rocket Pharma

New York (NY)

Rocket Pharma focuses on emerging gene-modified cell therapies to bring hope and relief to patients with under-treated rare diseases. The company is developing and commercializing numerous curative first-in-class gene therapies.

www.rocketpharma.com


 




News about Rocket Pharma



Rocket Pharma - Initiation of Research Coverage by William Blair & Company Announced

From William Blair & Company: Initiation of Research Coverage for Two Gene Therapy Companies –  William Blair & Company initiated research coverage of two gene therapy companies—Krystal Biotech, Inc. (KRYS $15.07) and Rocket Pharmaceuticals, Inc. (RCKT $19.17). Analyst Raju Prasad said that shares of Krystal Biotech hold a positive risk/reward profile ahead ...

Read More

Rocket Pharma partners with Stanford University to advance FA and PKD gene therapy research

From News Medical: Rocket Pharma partners with Stanford University to advance FA and PKD gene therapy research –  Rocket Pharmaceuticals, Inc. ("Rocket"), a leading U.S.-based multi-platform gene therapy company, and the Stanford University School of Medicine today announced a strategic collaboration to support the advancement of Fanconi Anemia (FA) and Pyruvate Kinase Deficiency (...

Read More


Rocket Pharmaceuticals and Inotek Pharmaceuticals Complete Merger Transaction

A recent article on Rocket Pharma merger and NASDAQ Listing –  Rocket Pharmaceuticals, Ltd., a leading U.S.-based multi-platform gene therapy company addressing challenging rare diseases, today announced the completion of its merger with Inotek Pharmaceuticals Corporation Rocket utilizes a multi-platform development approach that leverages the well-established lentivir...

Read More

Rocket Pharmaceuticals Appoints Gayatri R. Rao, M.D., J.D., Former U.S. FDA Director as Vice Preside

From Business Wire: Rocket Pharmaceuticals Appoints Gayatri R. Rao, M.D., J.D., Former U.S. FDA Director of the Office of Orphan Products Development, as Vice President, Regulatory Policy and Patient Advocacy –  Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) (“Rocket”), a leading U.S.-based multi-platform gene therapy company, today announced the appointment of Gayatri R. Rao, M.D....

Read More

Rocket Pharmaceuticals Receives FDA Regenerative Medicine Advanced Therapy (RMAT) and Fast Track Designations for RP-L102 Gene Therapy for Fanconi Anemia

From Business Wire –  NEW YORK--Nov. 27, 2018-- Rocket Pharmaceuticals, Inc. (Nasdaq: RCKT) (“Rocket”), a leading U.S.-based multi-platform gene therapy company, today announces that the U.S. Food and Drug Administration (FDA) has granted Regenerative Medicine Advanced Therapy (RMAT) and Fast Track designations to RP-L102, the Company’s lentiviral vector (LVV)-base...

Read More

Rocket Pharmaceuticals to Join Russell 3000® and 2000® Indexes

Press release on Rocket Pharma: Rocket Pharmaceuticals to Join Russell 3000® and 2000® Indexes –  NEW YORK--(BUSINESS WIRE) – Jun. 22, 2018 – Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) (“Rocket”), a leading U.S.-based multi-platform gene therapy company, announced that the Company will join the broad-market Russell 30...

Read More

Rocket Pharmaceuticals, Inc. (Nasdaq: RCKT) to Ring The Nasdaq Stock Market Closing Bell

A recent article on Rocket Pharma NASDAQ Listing –  Rocket Pharmaceuticals, Inc. (Nasdaq:RCKT), a leading U.S.-based multi-platform gene therapy company, will visit the Nasdaq MarketSite in Times Square. Rocket's common stock will be listed on the NASDAQ Global Market under the symbol "RCKT" and is expected to be begin trading on January 5, 2018. Read the full article  ...

Read More

Rocket Pharma's lead candidate shows positive effect in Fanconi anemia

From Seeking Alpha: Rocket Pharma's lead candidate shows positive effect in Fanconi anemia –  Results from a Phase 1/2 clinical trial evaluating Rocket Pharmaceuticals' (NASDAQ:RCKT) lead gene therapy candidate, RP-L102, in patients with Fanconi anemia (FA) showed a treatment effect. The data were presented at ASGCT in Chicago. ...

Read More